Global Stem Cell Characterization and Analysis Tool Market 2020 Leading Key Players Osiris Therapeutics, Inc., Cytori Therapeutics, Inc. – The Daily…

MarketsandResearch.biz has published the latest market research study on Global Stem Cell Characterization and Analysis Tool Market 2020 by Company, Regions, Type and Application, Forecast to 2025 which investigates a few critical features of the market such as industry condition, division examination, market insights. The report studies the global Stem Cell Characterization and Analysis Tool market share, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels. The report has referenced down to earth ideas of the market in a straightforward and unassuming way in this report. The research contains the categorization of the market by top players/brands, region, type, and end-user. The report exhaustive essential investigation of current market trends, opportunities, challenges, and detailed competitive analysis of the industry players in the market.

The research report has comprehensively included numbers and figures with the help of graphical and pictorial representation which embodies more clarity on the global Stem Cell Characterization and Analysis Tool market. Then the report delivers key information about market players such as company overview, total revenue (financials), market potential, global presence, as well as market share, prices, production sites and facilities, products offered, and strategies adopted by them. Market status and outlook of global and major regions, from angles of players, countries, product types, and end industries have been analyzed.

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/88052

Key strategic manufacturers included in this report: Osiris Therapeutics, Inc., Cytori Therapeutics, Inc., Astellas Pharma Inc., Caladrius Biosciences, Inc., Cellular Engineering Technologies Inc., U.S. Stem Cell, Inc., BioTime Inc., TEMCELL Technologies Inc., BrainStorm Cell Therapeutics Inc.

Market Potential:

Key market vendors have been predicted to obtain the latest opportunities as there has been an increased emphasis on spending more on the work of research and development by many of the manufacturing companies. Also, many of the market contenders are forecasted to make a foray into the emerging economies to find new opportunities. The global Stem Cell Characterization and Analysis Tool market has gone through rapid business transformation by good customer relationships, drastic and competitive growth, significant changes within the market, and technological advancement in this market.

Geographically, this report is segmented into several key countries, with market size, growth rate, import and export of in these countries from 2015 to 2020, which covering: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, etc.), Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

The market can be segmented into product types as: Services, Software, Instruments, Accessories, Consumables, Reagent and Assay Kits

The market can be segmented into applications as: Neurological Disorders, Orthopedic Treatments, Oncology Disorders, Diabetes, Other Therapeutic Applications, Drug Development and Discovery Embryonic Stem Cells Research

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/88052/global-stem-cell-characterization-and-analysis-tool-market-2020-by-company-regions-type-and-application-forecast-to-2025

Reasons for Buying Market Report:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact Us Mark Stone Head of Business Development Phone: +1-201-465-4211 Email: [emailprotected] Web: http://www.marketsandresearch.biz

See the original post here:
Global Stem Cell Characterization and Analysis Tool Market 2020 Leading Key Players Osiris Therapeutics, Inc., Cytori Therapeutics, Inc. - The Daily...

Researchers Discovers Cell in Zebrafish Critical to Brain Assembly and Function – Technology Networks

Read Time:

New research from Oregon Health & Science University for the first time documents the presence of astrocytes in zebrafish, a milestone that will open new avenues of research into a star-shaped type of glial cell in the brain that is critical for nearly every aspect of brain assembly and function.

The research was published this week in the journal Nature Neuroscience.

With their transparent bodies, zebrafish larvae provide a unique opportunity to gaze into the inner workings of the central nervous system, including the brain, even in living animals. The identification of astrocytes and the generation of tools to work with them in zebrafish will enable researchers around the world to open new lines of research to advance scientific understanding of how astrocytes function.

Astrocytes, it turns out, are the most abundant and mysterious cell type in the human brain, and OHSU is becoming a hub for research into their roles in development, brain function and disease.

"There is no neurodegenerative disease that I know of where astrocytes are not profoundly affected in some way," said senior author Kelly Monk, Ph.D., professor and co-director of the Vollum Institute at OHSU. "This gives us a powerful tool to get a handle on what these cells do and how they do it."

Monk and co-author Marc Freeman, Ph.D., credit lead author Jiakun Chen, Ph.D., a post-doctoral researcher in the Monk and Freeman labs, with developing a panoply of tools, including a cell-specific approach using the gene editing tool CRISPR to label and manipulate astrocyte precursors and incisively study their development and functions.

"He was able to capture the birth of an astrocyte from a stem cell and its entire development, which has never been visualized before in a vertebrate animal," Monk said.

Freeman said the discovery will dramatically enhance the study of how glia regulate brain development and physiology.

"This opens the door to experiments that you can't do in any other organism," Freeman said. "Zebrafish is the only animal in which you can now live-image all types of vertebrate glial cellsastrocytes, microglia, oligodendrocytes and OPCsalong with any neuron in intact neural circuits, from the earliest stages of development. Zebrafish is also the only vertebrate in which you can image the entire brain in live, behaving animals to figure out how it works. Understanding the role of these cells (astrocytes) in brain development will be key to understanding devastating neurodevelopmental disorders like autism spectrum disorder and schizophrenia.

"It's a major step forward and should power a lot of exciting work in the coming years."

Reference: Jiakun Chen, Kira E. Poskanzer, Marc R. Freeman & Kelly R. Monk. Live-imaging of astrocyte morphogenesis and function in zebrafish neural circuits, Nature Neuroscience,2020. DOI: 10.1038/s41593-020-0703-x

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read this article:
Researchers Discovers Cell in Zebrafish Critical to Brain Assembly and Function - Technology Networks

Brain Organoids Reveal the Early Stages of Angelman Syndrome – Technology Networks

Image of a human cerebral organoid at 9 weeks of development highlights the location of UBE3A proteins (in green), allowing researchers to track the behavior of UBE3A genes in different cells and at different stages of development. Image credit: Dilara Sen.

Read Time:

New research from North Carolina State University provides insights into the earliest stages of Angelman syndrome. The work also demonstrates how human cerebral organoids can be used to shed light on genetic disorders that affect human development.

Angelman syndrome is a genetic disorder associated with delayed development, intellectual disability, speech impairment and problems with movement. A great deal of research has been done on Angelman syndrome, primarily involving laboratory studies of mice and natural history studies of humans. However, while researchers have established that the complex disorder is tied to the behavior of a gene called UBE3A, and strong evidence in mice has shown that prenatal time periods may be important in disease development, researchers had yet to find a way of monitoring the earliest stages of the disease in human neural cells.

"Obviously we cannot do studies on developing humans, so we wanted to know whether it was possible to study the molecular dynamics around UBE3A using cerebral organoids," says Albert Keung, corresponding author of a paper on the work and an assistant professor of chemical and biomolecular engineering at NC State. "When is the gene turned on? How do drugs affect gene and neuronal functions? Does the gene behave differently in different types of cells? These are complex questions, but we found that you can learn a lot through the cerebral organoid model."

Human cerebral organoids are millimeter-sized tissues comprised of the cell types typically found in the different regions of the brain. They are made by culturing stem cells. For this study, the researchers monitored the behavior of the organoids for 17 weeks after culturing the cells.

For example, the researchers mapped when UBE3A was turned off or on in different types of cells and at different stages of neurodevelopment - as well as where in each cell the gene was active. This can shed light on things such as the extent to which UBE3A might be regulating the activity of other genes, and when the delivery of therapeutic treatments may be most effective.

One of the things the researchers discovered is that UBE3A appears to be playing an important role in the development of brain tissue earlier than anyone knew - potentially even within three weeks of culturing the organoids.

"We had the ability to see how UBE3A's behavior changed over time in the organoid," says Dilara Sen, first author of the paper and a Ph.D. student at NC State. "We were also able to see how different drugs affected the gene's behavior - and how those changes affected the function of neurons in the organoid."

"This is fundamental, proof-of-concept work," Keung says. "But hopefully it demonstrates how the cerebral organoid model can facilitate the development of therapeutic strategies for people with Angelman syndrome. We believe the model can do this by advancing our understanding of the disease, which can inform research into possible treatments. We also believe that this model could be used to screen drugs that are candidates for therapeutic interventions. Organoid models aren't new. But they may be more powerful tools than we previously anticipated."

Reference:

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Continued here:
Brain Organoids Reveal the Early Stages of Angelman Syndrome - Technology Networks

New data further reinforce Roche’s OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis – GlobeNewswire

September 11, 2020 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Basel, 11 September 2020 Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data that show OCREVUS (ocrelizumab) is a highly effective treatment option for people with relapsing-remitting multiple sclerosis (RRMS) who experienced a suboptimal response to their prior disease modifying therapy (DMT). Subgroup analysis from the two-year open-label Phase IIIb CASTING study also demonstrates that patients benefit across a wide range of disease related and demographic subgroups, regardless of prior treatment background. Findings will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

For a wide range of people with MS who experienced a suboptimal response to prior treatment, we continue to see evidence that OCREVUS provides significant benefit in slowing disease progression, said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. New real-world OCREVUS data show high persistence and adherence to the only B-cell therapy with a twice-yearly dosing schedule, which we know can be very important to both people with MS and their physicians.

Phase IIIb open-label CASTING study Approximately 75% of RRMS patients (492/658) had no evidence of disease activity (NEDA; brain lesions, relapses and worsening of disability) two years after switching to twice-yearly OCREVUS treatment (with prespecified MRI re-baselining at 8 weeks) in the primary analysis of the CASTING study. Patients enrolled in the study had prior suboptimal response to at least six months of treatment with up to two DMTs. The analysis also showed the proportion of patients achieving NEDA remained consistently high across all measured patient subgroups, including baseline MRI activity, relapse activity, disability level, age and the number of prior DMTs. Further, 78% of patients treated with only one prior DMT compared with 70% of patients treated with two prior DMTs achieved NEDA.

Additionally, patients treated with OCREVUS experienced an improvement in the majority of symptoms measured by SymptoMScreen after two years. SymptoMScreen is a patient-reported outcome tool to assess symptom severity across twelve domains. The most pronounced significant improvements (p<0.001) were seen in sensory symptoms, fatigue and vision, which are important for daily living.

CONFIDENCE real-world safety study A 97% treatment persistence for OCREVUS patients at 18 months, and strong adherence to infusions every six months, was seen in an interim analysis of more than 1,600 patients in the ongoing German CONFIDENCE study. Separate data from a U.S. commercial claims database that support high persistence and sustained adherence to OCREVUS treatment will also be presented.

OCREVUS longer-term safety data New safety data as of January 2020 will be presented, representing 5,680 patients with RMS and PPMS and 18,218 patient-years of exposure to OCREVUS, across all OCREVUS clinical trials. These findings further demonstrate the consistently favourable benefit-risk profile of OCREVUS over seven years.

With rapidly growing real-world experience and more than 170,000 people treated globally, OCREVUS has twice-yearly (six-monthly) dosing and is the first and only therapy approved for RMS (including relapsing-remitting MS [RRMS] and active, or relapsing, secondary progressive MS [SPMS], in addition to clinically isolated syndrome [CIS] in the U.S.) and primary progressive MS (PPMS). OCREVUS is approved in 92 countries across North America, South America, the Middle East, Eastern Europe, as well as in Australia, Switzerland and the European Union.

About multiple sclerosis Multiple sclerosis (MS) is a chronic disease that affects nearly 1 million people in the U.S. and more than 2.3 million people worldwide. MS occurs when the immune system abnormally attacks the insulation and support around nerve cells (myelin sheath) in the central nervous system (brain, spinal cord and optic nerves), causing inflammation and consequent damage. This damage can cause a wide range of symptoms, including muscle weakness, fatigue and difficulty seeing, and may eventually lead to disability. Most people with MS experience their first symptom between 20 and 40 years of age, making the disease the leading cause of non-traumatic disability in younger adults.

People with all forms of MS experience disease progression permanent loss of nerve cells in the central nervous system and gradual worsening of disability at the beginning of their disease even if their clinical symptoms arent apparent or dont appear to be getting worse. Delays in diagnosis and treatment can negatively impact people with MS, both in terms of their physical, mental and financial health. An important goal of treating MS is to slow the progression of disability as early as possible.

Relapsing-remitting MS (RRMS) is the most common form of the disease and is characterised by episodes of new or worsening signs or symptoms (relapses) followed by periods of recovery. Approximately 85% of people with MS are initially diagnosed with RRMS. The majority of people who are diagnosed with RRMS will eventually transition to secondary progressive MS (SPMS), in which they experience steadily worsening disability over time. Relapsing forms of MS (RMS) include people with RRMS and people with SPMS who continue to experience relapses. Primary progressive MS (PPMS) is a debilitating form of the disease marked by steadily worsening symptoms but typically without distinct relapses or periods of remission. Approximately 15% of people with MS are diagnosed with the primary progressive form of the disease. Until the FDA approval of OCREVUS, there had been no FDA approved treatments for PPMS.

About OCREVUS (ocrelizumab) OCREVUS is the first and only therapy approved for both RMS (including clinically isolated syndrome, RRMS and active, or relapsing, SPMS, in addition to CIS in the U.S.) and PPMS. OCREVUS is a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage. This nerve cell damage can lead to disability in people with MS. Based on preclinical studies, OCREVUS binds to CD20 cell surface proteins expressed on certain B cells, but not on stem cells or plasma cells, suggesting that important functions of the immune system may be preserved. OCREVUS is administered by intravenous infusion every six months. The initial dose is given as two 300 mg infusions given two weeks apart. Subsequent doses are given as single 600 mg infusions.

About Roche in multiple sclerosis Roche is following the science in an effort to ultimately stop disease progression and preserve function in people living with multiple sclerosis (MS). As a company, we continue to advance the clinical understanding of MS and progression with the aim of bringing the most benefit to people living with MS.

About Roche in neuroscience Neuroscience is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases.

Roche is investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, neuromyelitis optica spectrum disorder, Alzheimers disease, Huntingtons disease, Parkinsons disease, Duchennes muscular dystrophy and autism spectrum disorder. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today.

About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve peoples lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the worlds largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit http://www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Group Media Relations Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Here is the original post:
New data further reinforce Roche's OCREVUS (ocrelizumab) as a highly effective treatment for people with multiple sclerosis - GlobeNewswire

Adipose Tissue-Derived Stem Cells (ADSCS) Market to Witness High Growth in Near Future – Good Night, Good Hockey

Data Bridge Market Research has recently published the Global research Report TitledAdipose Tissue-Derived Stem Cells (ADSCS) Market. The study provides an overview of current statistics and future predictions of the Global Adipose Tissue-Derived Stem Cells (ADSCS) Market.The study highlights a detailed assessment of the Market and displays market sizing trends by revenue & volume (if applicable), current growth factors, expert opinions, facts, and industry validated market development data.

Adipose tissue-derived stem cells (ADSCS) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account grow at a CAGR of 6.1% in the above-mentioned forecast period. The accelerating application of adipose tissue-derived stem cells (ADSCS) in the regenerative medicines research, development of cell linage, tissue engendering, bone and cartilage regeneration are driving the exponential growth of adipose tissue-derived stem cells (ADSCS) market during the forecast period of 2020 to 2027.

Get a Free Sample Copy Of This Research Report + All Related Graphs & Charts:https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market&utm_source=&kA

The report gives explanations about market definition, currency and pricing, market segmentation, market overview, premium insights, key insights and company profile of the key market players. With this large scale Adipose Tissue-Derived Stem Cells (ADSCS) Marketreport, it can also be estimated how the actions of key players are affecting the sales, import, export, revenue and CAGR values. The report also helps analyse the most appropriate method for the distribution of certain products. This market study also estimates the market status, market share, growth rate, sales volume, future trends, market drivers, market restraints, revenue generation, opportunities and challenges, risks and entry barriers, sales channels, and distributors

Top Key Vendors Covered in the report:

Antria Inc., CELGENE CORPORATION, pluristem, Tissue Genesis, Cytori Therapeutics Inc., PRECIGEN, Mesoblast Ltd, CORESTEM, Inc, among other domestic and global players.

Regions included:

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, and Italy)

Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

South America (Brazil, Argentina, Colombia)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

How Does This Market Insights Help?

Key Pointers Covered in the Adipose Tissue-Derived Stem Cells (ADSCS) Market Industry Trends and Forecast to 2026

Reasons to Purchase this Report

A complete value chain of the global Adipose Tissue-Derived Stem Cells (ADSCS) market is presented in the research report. It is associated with the review of the downstream and upstream components of the Adipose Tissue-Derived Stem Cells (ADSCS) Market. The market is bifurcated on the basis of the categories of products and customer application segments. The market analysis demonstrates the expansion of each segment of the global Adipose Tissue-Derived Stem Cells (ADSCS) market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Adipose Tissue-Derived Stem Cells (ADSCS) market.

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market&utm_source=&KA

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Market Drivers

Market Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

Any Questions? Speak to Analyst:https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-adipose-tissue-derived-stem-cells-adscs-market&utm_source=&KA

Customization of the Report

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thanks for reading this article you can also get individual chapter wise section or region wise report versions like North America, Europe, MEA or Asia Pacific.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rates

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

See the original post:
Adipose Tissue-Derived Stem Cells (ADSCS) Market to Witness High Growth in Near Future - Good Night, Good Hockey

New Age Meats: "There’s a Reason We’re Called New Age Meats. The Definition of Meat is Changing." – vegconomist – the vegan business…

New Age Meats: Theres a Reason Were Called New Age Meats. The Definition of Meat is Changing.

We were fascinated to speak with New Age Meats CEO Brian Spears.

You have created a pork sausage already, what other products are you currently working on?One of the reasons we chose pork is that its the most commonly consumed animal in the world. Were working on other pork products for both Western and Asian markets. Weve also done work with other animals.

We understand that your product development is focused on interrogating the science of meat, to understand why it tastes and feels the way it does, can you tell us more about that?How do cells make the sensory characteristics that we care about? To understand that, we start with the human perception of meat. This allows us to see the biomarkers that we can then have the cells make more efficiently.

Why is cellbased meat important right now and how much potential to disrupt animal agriculture do you believe it offers as a segment?Were pretty open that we make blended products of cultivated and plant based meat, but the real question is that of demand and our planets ability to supply the food required to feed ourselves. The UNFAO predicts that we will need to grow our food supply by 70% by 2050, a growth rate which outpaces our land and resource availability. Were not seeking disruption so much as augmentation to meet that increased demand.

We covered a report from the GAO back in May that stated that cell-based meat is stuck in the Research and Development stage, what are your thoughts on this?The GAO performs invaluable services, but innovation is not one of them. Thinking that the pathway forward is to convert existing technologies in industries like biopharma and cellular therapeutics leads one to believe that the industry has a long way to go. Creating new pathways through whitespace is what startups do.

New Age Meats has secured $5M in funding to date; investors seem keen to be a part of this fledgling industry despite concerns noted from the GAO, will you be announcing further funding rounds? Absolutely. Alternative proteins comprise less than half a percent of the massive worldwide meat market. Well never make a dent in that market if we grow slowly. We make the future of meat, and investors are eager to join us in that journey.

Can we expect to see your pork sausage in the market in the near future? What challenges do you face with this?Yes! Were continually dropping the cost and ramping up production. Here in the US, regulators are moving quickly to allow us to come to market, and thats mirrored by other countries, notably in Asia.

Where do you see New Age Meats in the next five years?Pork products are where we start. In the next five years, well have multiple types of meat products in different geographies and distribution channels.

Link:
New Age Meats: "There's a Reason We're Called New Age Meats. The Definition of Meat is Changing." - vegconomist - the vegan business...

Global Wearable Artificial Organs Market Is Expected to Reach USD 17.48 billion by 2027 : Fior Markets – GlobeNewswire

September 08, 2020 08:02 ET | Source: Fior Markets

Newark, NJ, Sept. 08, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, theglobal wearable artificial organs market is expected to grow from USD 5.26 billion in 2019 and to reach USD 17.48 billion by 2027, growing at a CAGR of 16.20% during the forecast period 2020-2027.

The rising demand and supply gap of organ donors, along with the increasing frequency of organ failure, is driving the market growth. Technological advancement and continuous investments in research and development activities for wearable artificial organs also boost the market growth. The artificial organ is an engineered tool integrated into human living tissues to substitute the human organ. The requirement for wearable artificial organs is increasing due to less cost of wearable artificial organs than organ transplantation and the growing number of geriatric populations prone to kidney failure. Leading players in the industry are emphasizing on the advancement of wearable artificial organs for the disease that cannot be cured with alternative techniques. Wearable and portable devices would potentially enhance the quality of life by enabling patients to continue their daily activities while undergoing therapy or dialysis. Improvement in the field of stem cell, microelectronics, nanotechnology, artificial intelligence, genetic engineering, genomics, proteomics, and bioinformatics is generating new avenues for wearable artificial organs.

Artificial organs are synthetic machines or devices that replace several human organs that undergo from the malfunctioning or loss of complete functioning ability. Artificial organs are constructed from human stem cells and then developed in laboratories. However, advancements and innovation of modern artificial organs are still improving, offering significant growth outlooks to the global artificial organs market during the forecast period. An artificial organ is an engineered tissue or tool that is implanted into the human body. The artificial organs replace a natural organ to replicate a distinct function so that the patient can return to a healthy life. It is a remedial tool with a biochemical or mechanical function such as lung, heart, liver, kidney, or neurosensory organs.

Producers in the industry are focused on organ repair and biological replacement that will operate as a tissue-based artificial organ and simulates a physiological function of an organ. The devices are customized to the changing needs of the patients. The market for wearable artificial organs is shifting from mechanical alternative towards original biological replacement. Moreover, the machines are less expensive than organ transplants, thereby generating new opportunities and demand in the market. Improving healthcare infrastructure and decreasing waiting time for FDA permission are also factors that augment market growth. For instance, in August 2019, FDA authorized MED-EL Cochlear Implant System for asymmetric hearing loss. The system is utilized for children five years and older. A high number of permanent injuries, as well as rising incidence of road accidence, are also creating demand for wearable artificial organs.

DOWNLOAD FREE SAMPLE REPORT AThttps://www.fiormarkets.com/report-detail/418835/request-sample

Key players operating in the global wearable artificial organs market include Medtronic, AWAK Technology, Second Sight Medical Products, Inc., Cochlear Ltd., Ekso bionics, MED-EL, Abbott Laboratories, Boston Scientific, HDT Global, Touch Bionics, Inc., Neurotron Biotechnology, Retina Implant AG, ReWalk Robotics, Rex Bionics Plc., Suit X (U.S. Bionics Inc.) and Lockheed Martin Corporation. To gain a significant market share in the global wearable artificial organs market, the key players are now focusing on adopting strategies such as product innovations, mergers & acquisitions, recent developments, joint ventures, collaborations, and partnerships.

The cochlear implant segment dominated the market and held the largest market share of 19.07% in the year 2019 The product segment includes vision bionics, brain bionics, bionic limbs, exoskeleton, cochlear implants, pancreas and kidney. The cochlear implants segment held the highest share of 19.07% in the wearable artificial organs market in 2019 due to frequent product launches. In December 2019, the FDA authorized the first active Osseointegrated steady-state implant, which can be utilized for children of 12 years and older with single-sided sensorineural deafness. The device would help in enhancing the patients capacity to hear in both quiet and noisy situations.

The electronic segment dominated the market and valued at USD 2.85 billion in the year 2019 The technology segment includes electronic and mechanical. The electronic segment held the highest share of UDS 2.85 billion in the wearable artificial organs market in 2019. It is due to the rising adoption of electronic wearable artificial organs and technological advancement. The need for electronic wearable artificial organs among amputees is rising. Electronic and battery systems are utilized to generate muscle and nerve movement in the remaining organ. The devices are creating a revolution in the therapeutic electronics industry. The market is anticipated to observe innovative product launches over the forecast period. For instance, in June 2020, Medtronic exhibited the positive results of MiniMed 780G System, its artificial pancreas. The device would give both basal insulin and correction boluses every five minutes to serve patients to avoid high and lows of insulin with greater comfort.

Browse full report with TOC athttps://www.fiormarkets.com/report/wearable-artificial-organs-market-by-product-vision-bionics-418835.html

Regional Segment Analysis of Global Wearable Artificial Organs Market

On the basis of geography, the global wearable artificial organs market is classified into North America, Europe, South America, Asia Pacific, and Middle East and Africa. North America had the largest share of 26.38% in the wearable artificial organs market in 2019. Rising research and development investment and speedy FDA permissions of the wearable artificial organs boost the demand in the region. The presence of significant market players and extremely modern healthcare infrastructure is also increasing the application in the region. In North America, the U.S. dominated the market due to factors such as favorable reimbursement policies, large patient pool, and deepening shortage of organ donors.

Request for Customization:https://www.fiormarkets.com/enquiry/request-customization/418835

About the report: The global wearable artificial organs market is analyzed on the basis of value (USD Billion), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porters five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

For Instant Purchase:https://www.fiormarkets.com/checkout.html?reportid=418835&type=single

Customization of the Report:

The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

About Fior Markets

Fior Markets is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports. Fior Markets deploys a wide range of regional and global market intelligence research reports including industries like technology, pharmaceutical, consumer goods, food and beverages, chemicals, media, materials and many others. Our Strategic Intelligence capabilities are purposely planned to boost your business extension and elucidate the vigor of diverse industry. We hold distinguished units of highly expert analysts and consultants according to their respective domains. The global market research reports we provide involve both qualitative and quantitative analysis of current market scenario as per the geographical regions segregated and comprehensive performance in different regions with global approach. In addition, our syndicated research reports offer a packaged guide to keep companies abreast of the upcoming major restyle in their domains. Fior Markets facilitates clients with research analysis that are customized to their exact requirements, specifications and challenges, whether it is comprehensive desk research, survey work, composition of multiple methods, in-detailed interviewing or competitive intelligence. Our research experts are experienced in matching the exact personnel and methodology to your business need.

Contact Us

Avinash D Head of Business Development Phone:+1-201-465-4211 Email:sales@fiormarkets.com Web:www.fiormarkets.com

To Read Top Industries Reports, Visit our Affiliated Website: https://researchstore.biz/

Related Reports Enteral Feeding Devices Market - https://www.fiormarkets.com/report/enteral-feeding-devices-market-by-type-enteral-feeding-418637.html Insulin Storage Devices Market - https://www.fiormarkets.com/report/insulin-storage-devices-market-by-type-insulated-kits-418526.html Healthcare Analytical Testing Services Market - https://www.fiormarkets.com/report/healthcare-analytical-testing-services-market-by-type-stability-418517.html Extracorporeal Membrane Oxygenation (ECMO) Market - https://www.fiormarkets.com/report/extracorporeal-membrane-oxygenation-ecmo-market-by-component-accessories-418492.html

View post:
Global Wearable Artificial Organs Market Is Expected to Reach USD 17.48 billion by 2027 : Fior Markets - GlobeNewswire

Global Organoids and Spheroids Market Is Expected to Reach USD 2794.79 Million by 2027 : Fior Markets – Yahoo Finance

Organoids and Spheroids Market by Type (Organoids and Spheroids), Application (Personalized Medicine, Developmental Biology, Drug Toxicity and Efficacy Testing, Disease Pathology Testing and Regenerative Medicine), End-Use, Region, Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2020 to 2027

Newark, NJ, Sept. 08, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global organoids and spheroids market is expected to grow from USD 502.92 million in 2019 and to reach USD 2794.79 million by 2027, growing at a CAGR of 23.91 % during the forecast period 2020-2027.

The growing prevalence of chronic disorders in recent times has increased the demand for effective drugs. The organoids and spheroids model is increasingly becoming popular as they provide a better perspective for human developmental biology research. The organoids model reveals the effects of covid-19 on several intestinal cells. Thus, these models are playing a significant role in the vaccine development process. The rise in demand for diagnostics and therapeutics solutions for these chronic diseases is fuelling market growth.

The organoids and spheroids are the three-dimensional structures that replicate the condition of different tissues present in the human body. The organoids model works as an in-vitro model for the study of biological development. The organoids can be established for organs such as kidney, retina, brain, liver, small and large intestine, lungs, etc. The organoids can be derived from a single adult stem cell or the embryonic stem cell. On the other hand, spheroids consist of a cluster of cells. These are derived from both the single-cell type and multi-cellular stems. The organoids and spheroids differ in the driving force required for the development. The organoids are formed by internal development processes and spheroids forms by adhesion of cells to each other. These also differ in the time duration for which the 3D culture can be maintained.

The human organoids have helped in the analysis of many tissues, which helps in a better understanding of the working of the organs. The 3D models of human organs have opened up opportunities for conducting various studies and experiments to analyze the effects of drugs on different organs. It also has provided potential ways of organ transplantation. Further, the growing technological advancements in the spheroid and organoid 3D models are fuelling the market growth. Apart from this, the major players operating in the market are also focusing on facilitating cell activities by taking control of the microenvironment of the culture.

DOWNLOAD FREE SAMPLE REPORT AThttps://www.fiormarkets.com/report-detail/418832/request-sample

Key players operating in the organoids and spheroids market are 3D Biotek LLC, 3D Biomatrix, ATCC, Cellesce Ltd., Hubrecht Organoid Technology (HUB), Merck KGaA, STEMCELL Technologies Inc., Corning Incorporated, AMS Biotechnology Limited, Perkin Elmer, Kuraray, Thermo Fisher Scientific, Inc., Greiner Bio-One, Prellis Biologics, Lonza and others. The major players in the organoids and spheroids market are focusing on expansionary strategies such as mergers & acquisitions, recent developments, joint ventures, collaborations, product innovations and partnerships. These strategies would extract higher market shares for the players and thus strengthen their position in the global market. Thermo Fisher Scientific and Corning Incorporated are some of the biggest manufacturers and suppliers of organoids and spheroids in the global market.

Spheroids segment dominated the market and held the largest market share of 54.92% in the year 2019

On the basis of type segment, the global organoids and spheroids market includes organoids and spheroids. The organoids are segmented into product type, techniques and source. The product type of organoids includes neural organoids, intestinal organoids, hepatic organoids and others. The techniques include crypt organoid culture techniques, general submerged technique, clonal organoid from Lgr5+ cells, air-liquid interface (ALI) method and brain and retina organoid formation protocol. The sources segment includes primary tissues and stem cells. The spheroids are also segmented into product type, techniques and source. The product type of spheroids includes mammospheres, neurospheres, embryoid bodies, multi-cellular tumor spheroids and hepatospheres. The techniques segment includes hanging drop method, micropatterned plates, low cell attachment plates and others. The source of spheroid includes primary cells, cell line and iPSCs derived cells. Spheroids dominated the market and held the largest market share of 54.92% in the year 2019. The spheroids are in high demand owing to its increased application in cancer research and drug discovery. The spheroids can be cultured to produce cells of consistent shape, which can be used for thorough analysis. Further, the organoids segment is projected to register an impressive growth rate as these are used as in-vitro models in the process of drug discovery. The segment is expected to be driven by the intestinal organoids type owing to the increased application is cell biology and disease modeling.

Story continues

Developmental biology segment dominated the market and held the largest market share of 28.65% in the year 2019

On the basis of the application segment, the global organoids and spheroids market includes personalized medicine, developmental biology, drug toxicity and efficacy testing, disease pathology testing and regenerative medicine. Developmental biology dominated the market and held the largest market share of 28.65% in the year 2019. The organoids which are derived from induced pluripotent stem cells and embryonic stem cells are useful in human developmental biology. The spheroids and organoids have been increasingly used in the development biology study of the pancreas, kidney, stomach, liver, etc. for the purpose of embryonic development, tissue homeostasis and lineage specification.

Biotechnology and pharmaceutical companies segment dominated the market and held the largest market share of 39.82% in the year 2019

The end-user segment includes academic and research institutes, hospitals and diagnostic centers and biotechnology and pharmaceutical companies. Biotechnology and pharmaceutical companies segment dominated the market and held the largest market share of 39.82% in the year 2019. The organoids and spheroids are mainly used in clinical applications owing to the vast scope of the experiment. Thus, the biotechnology and pharmaceutical companies are using these increasingly in the drug discovery processes.

Browse full report with TOC athttps://www.fiormarkets.com/report/organoids-and-spheroids-market-by-type-organoids-and-418832.html

Regional Segment Analysis of the Organoids and Spheroids Market

On the basis of geography, the global organoids and spheroids market is classified into North America, Europe, South America, Asia Pacific, and the Middle East and Africa. North America region accounted for a significant market share of 43.02% in the year 2019. The region has been lately, investing in the organoid and spheroids based research models. Further, the growing technological advancements provides a platform for extensive research on 3D models of human tissue structure for the development of personalized and regenerative medicines. However, Asia-Pacific is expected to register the highest growth rate during the forecast period. The growing patient population owing to the prevalence of chronic diseases has led to the development of the market in the region. Further, the growth of stem cell research has increased the demand for organoids and spheroids.

Request for Customization:https://www.fiormarkets.com/enquiry/request-customization/418832

About the report:

The global organoids and spheroids market is analyzed on the basis of value (USD Million). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter's five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

For Instant Purchase:https://www.fiormarkets.com/checkout.html?reportid=418832&type=single

Customization of the Report:

The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

About Fior Markets

Fior Markets is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports. Fior Markets deploys a wide range of regional and global market intelligence research reports including industries like technology, pharmaceutical, consumer goods, food and beverages, chemicals, media, materials and many others. Our Strategic Intelligence capabilities are purposely planned to boost your business extension and elucidate the vigor of diverse industry. We hold distinguished units of highly expert analysts and consultants according to their respective domains. The global market research reports we provide involve both qualitative and quantitative analysis of current market scenario as per the geographical regions segregated and comprehensive performance in different regions with global approach. In addition, our syndicated research reports offer a packaged guide to keep companies abreast of the upcoming major restyle in their domains. Fior Markets facilitates clients with research analysis that are customized to their exact requirements, specifications and challenges, whether it is comprehensive desk research, survey work, composition of multiple methods, in-detailed interviewing or competitive intelligence. Our research experts are experienced in matching the exact personnel and methodology to your business need.

Contact Us

Avinash D Head of Business Development Phone:+1-201-465-4211 Email:sales@fiormarkets.com Web:www.fiormarkets.com

To Read Top Industries Reports, Visit our Affiliated Website: https://www.marketquest.biz

Related Reports Hydroxychloroquine Market - https://www.fiormarkets.com/report/hydroxychloroquine-market-by-dosage-type-200-mg-400-417942.html Immunotherapy Drugs Market - https://www.fiormarkets.com/report/immunotherapy-drugs-market-by-drug-type-checkpoint-inhibitors-417899.html Bovine Lactoferrin Market - https://www.fiormarkets.com/report/bovine-lactoferrin-market-by-type-freeze-dried-and-milled-417794.html CBD Hemp Oil Market - https://www.fiormarkets.com/report/cbd-hemp-oil-market-by-type-pure-cbd-411566.html

Original post:
Global Organoids and Spheroids Market Is Expected to Reach USD 2794.79 Million by 2027 : Fior Markets - Yahoo Finance

Competitive Scenario of Animal Stem Cell Therapy Market Growth, Size, Demand, Forecast with Depth Assessment by Top Key Players 2025 – Scientect

Key Questions Answered in The Report:

Purchase this report (Price With the slowdown in world economic growth, the Animal Stem Cell Therapy industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Animal Stem Cell Therapy market size to maintain the average annual growth rate of 0.148698354997 from 8.0 million USD in 2014 to 16.0 million USD in 2019, Report analysts believe that in the next few years, Animal Stem Cell Therapy market size will be further expanded, we expect that by 2024, The market size of the Animal Stem Cell Therapy will reach 80.0 million USD. USD for single user license)https://www.360researchreports.com/purchase/15079719

Major Highlights of TOC:

1 Report Overview

1.1 Study Scope

1.2 Key Market Segments

1.3 Regulatory Scenario by Region/Country

1.4 Market Investment Scenario Strategic

1.5 Market Analysis by Type

1.5.1 Global Animal Stem Cell Therapy Market Share by Type (2020-2026)

1.6 Market by Application

1.6.1 Global Animal Stem Cell Therapy Market Share by Application (2020-2026)

2.Global Market Growth Trends

2.1 Industry Trends

2.1.1 SWOT Analysis

2.1.2 Porters Five Forces Analysis

2.2 Potential Market and Growth Potential Analysis

2.3 Industry News and Policies by Regions

2.3.1 Industry News

2.3.2 Industry Policies

3 Value Chain of Animal Stem Cell Therapy Market

3.1 Value Chain Status

3.2 Animal Stem Cell Therapy Manufacturing Cost Structure Analysis

3.2.1 Production Process Analysis

3.2.2 Manufacturing Cost Structure of Electric Cookers

3.2.3 Labor Cost of Electric Cookers

4 Players Profiles

4.1 Media

4.1.1 Medea Basic Information

4.1.2 Animal Stem Cell Therapy Product Profiles, Application and Specification

4.1.3 Medea Animal Stem Cell Therapy Market Performance (2015-2020)

4.1.4 Medea Business Overview

5 Global Animal Stem Cell Therapy Market Analysis by Regions

5.1 Global Animal Stem Cell Therapy Sales, Revenue and Market Share by Regions

5.1.1 Global Animal Stem Cell Therapy Sales by Regions (2015-2020)

5.1.2 Global Animal Stem Cell Therapy Revenue by Regions (2015-2020)

5.2 North America Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

5.3 Europe Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

5.4 Asia-Pacific Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

Request for Customization @ https://www.360researchreports.com/TOC/15079719#TOC

6 North America Animal Stem Cell Therapy Market Analysis by Countries

6.1 North America Animal Stem Cell Therapy Sales, Revenue and Market Share by Countries

6.1.1 North America Animal Stem Cell Therapy Sales by Countries (2015-2020)

6.1.2 North America Animal Stem Cell Therapy Revenue by Countries (2015-2020)

6.2 United States Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

7 Europe Animal Stem Cell Therapy Market Analysis by Countries

7.1 Europe Animal Stem Cell Therapy Sales, Revenue and Market Share by Countries

7.1.1 Europe Animal Stem Cell Therapy Sales by Countries (2015-2020)

7.1.2 Europe Animal Stem Cell Therapy Revenue by Countries (2015-2020)

7.2 Germany Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

7.3 UK Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

7.4 France Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

7.5 Italy Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

8 Asia-Pacific Animal Stem Cell Therapy Market Analysis by Countries

8.1 Asia-Pacific Animal Stem Cell Therapy Sales, Revenue and Market Share by Countries

8.1.1 Asia-Pacific Animal Stem Cell Therapy Sales by Countries (2015-2020)

8.1.2 Asia-Pacific Animal Stem Cell Therapy Revenue by Countries (2015-2020

8.2 China Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

8.3 Japan Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

Continued.

Animal Stem Cell Therapy Market Key Benefits

About Us:

360 Research Reports is the credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Research Reports, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact Us:

Name: Mr. Ajay More

Email: [emailprotected]

Organization: 360 Research Reports

Phone: +44 20 3239 8187/ +14242530807

For More Related Reports Click Here :

Global Amoxycillin Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026

Global Diatom Mud Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026

Europe Sensors Industry Market Research Report

Global Pain Management Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026

Global Histology and Cytology Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026

Originally posted here:
Competitive Scenario of Animal Stem Cell Therapy Market Growth, Size, Demand, Forecast with Depth Assessment by Top Key Players 2025 - Scientect

D&D Pharmatech Announces Launch of Valted Seq Subsidiary Focusing on Discovery of Neurodegenerative Disease Pathways and Biomarkers to Support…

GYEONGGI-DO, South Korea & GAITHERSBURG, Md.--(BUSINESS WIRE)--D&D Pharmatech, Inc. (D&D), a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, today announced the launch of their fourth subsidiary, Valted Seq. D&D Pharmatech is also the parent company of Neuraly, Precision Molecular, and Theraly Fibrosis.

Valted Seq is focused on the discovery of neurodegenerative pathways and biomarkers to inform and accelerate development of new therapeutics and diagnostics, including companion diagnostics which play a critical role in enabling advanced therapeutics. To achieve this, the company has created the worlds largest repository of single-cell sequencing data from high-quality, clinically characterized brain tissues of patients with neurodegenerative diseases including Alzheimers and Parkinsons.

We are excited to be a member of the D&D Pharmatech family of companies and are grateful for their investment which will ultimately improve our ability to diagnose and treat neurodegenerative diseases, said Valina Dawson, Ph.D., Interim Chief Executive Officer of Valted Seq. Valted Seq was founded on the belief that a deeper understanding of neurodegenerative pathways is essential to develop precision therapeutics and identify novel biomarkers to diagnose, guide therapies and monitor some of our most challenging and devastating diseases. We expect this unprecedented repository of single-cell genomics, which Valted Seq will explore using advanced big data analytics, will accelerate progress towards better outcomes for patients. Dr. Dawson is Director of the Neuroregeneration and Stem Cell Programs in the Institute for Cell Engineering at the Johns Hopkins University.

The ongoing collection and comprehensive analysis of thousands of brain tissue samples using Valted Seqs state-of-the-art single-cell analysis technology will support a number of projects including development of a first-in-class liquid biopsy assay for blood-based biomarkers for detection and monitoring of Parkinsons disease. The assay is being developed to be utilized in both internal and external clinical trials for emerging Parkinsons therapies; Valted Seq has already been approached by pharmaceutical companies seeking access to the proprietary biomarker assays. The company continues to expand and has added experienced leaders in bioinformatics and diagnostics to advance the technology through product development and towards commercialization.

We are excited to introduce Valted Seq as one of D&Ds companies, said Dr. Seulki Lee, Chief Executive Officer of D&D Pharmatech. Our subsidiaries, which to date have originated from technologies from leading research institutes, are examples of how D&D and academia have worked in close collaboration to build a powerful engine to accelerate translation of innovation from the academic setting into a framework for commercialization. The launch of Valted Seq exemplifies this successful type of collaboration and represents a model that D&D is extending to other preeminent universities.

In recent years, D&D has invested more than $7 million in sponsored research at leading medical research institutions to advance potentially game-changing healthcare innovations.

By establishing a set of subsidiaries that cover the full spectrum of screening, diagnosis, therapy and therapeutic monitoring of diseases affecting the central nervous system, D&D is creating synergies that would not otherwise be achievable. Three subsidiaries are enabling a comprehensive Total Care approach to neurodegeneration: Valted Seq is identifying novel biomarkers for diagnosing and screening Parkinsons and Alzheimers disease; Precision Molecular is advancing neuromolecular imaging to identify and/or follow patients for therapies being developed by Neuraly and is developing new imaging biomarkers based on Valted Seq discoveries. The academic founders of these subsidiaries remain deeply engaged with each other and industry experts, enabling D&D to create a continuum from groundbreaking science to innovative pipelines.

About D&D Pharmatech

D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. This corporate structure creates a unique opportunity to accelerate translation of cutting-edge research into lifesaving therapeutic products for patients. The companys product pipeline focuses on a range of indications including neurodegenerative and fibrotic diseases. D&D Pharmatech is the parent company of U.S.-based Neuraly Inc., Theraly Fibrosis Inc., Precision Molecular Inc. and Valted Seq, Inc. For more information, please visit http://www.ddpharmatech.com/

Continued here:
D&D Pharmatech Announces Launch of Valted Seq Subsidiary Focusing on Discovery of Neurodegenerative Disease Pathways and Biomarkers to Support...